Skip to content

Clinical trials

Phase 3 Carcinoma, Transitional Cell trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Carcinoma, Transitional Cell Phase: Phase 3 Country / region: China Clear all

11 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20151
20161
20192
20222
20241
20252
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting6
Completed2
Active, not recruiting1
Terminated1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Hoffmann-La Roche2
AstraZeneca1
BeiGene1
Eli Lilly and Company1
Mabwell (Shanghai) Bioscience Co., Ltd.1
Merck Sharp & Dohme LLC1
RemeGen Co., Ltd.1
Shanghai Junshi Bioscience Co., Ltd.1
Sichuan Baili Pharmaceutical Co., Ltd.1
Suzhou Suncadia Biopharmaceuticals Co., Ltd.1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Carcinoma, Transitional Cell11
Urinary Bladder Neoplasms3
Carcinoma1
Neoplasm Metastasis1

Trials

Showing 1 to 11 of 11. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.